References:
1. CDC. Asthma: most recent national asthma data. Atlanta, GA:US
Department of Health and Human Services, CDC .
https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm.
2020.
2. Nielsen AO, Qayum S, Bouchelouche PN, Laursen LC, Dahl R, Dahl M.
Risk of asthma in heterozygous carriers for cystic fibrosis: A
meta-analysis. J Cyst Fibros. 2016;15(5):563-7.
3. Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG. DeltaF508
heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet.
1998;351(9120):1911-3.
4. Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D,
et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a
Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-19.
5. de Vries HG, Collee JM, de Walle HE, van Veldhuizen MH, Smit Sibinga
CT, Scheffer H, et al. Prevalence of delta F508 cystic fibrosis carriers
in The Netherlands: logistic regression on sex, age, region of residence
and number of offspring. Hum Genet. 1997;99(1):74-9.
6. Claustres M, Altieri JP, Guittard C, Templin C, Chevalier-Porst F,
Des Georges M. Are p.I148T, p.R74W and p.D1270N cystic fibrosis causing
mutations? BMC Med Genet. 2004;5:19.